Highly focused (obsessed?) and gifted (maybe just obsessed?) scientist studying "bugs as drugs" for cancer immunotherapy. Views (including this one) are my own!
Very honored to be starting a new faculty position in the Department of Surgery at the University of Texas Medical Branch (UTMB) in Galveston! Thanks to all those who made this transition possible! @utmbhealth@JochenReiser@KlimbergV@UTMBSurgery
This team science paper offers a mechanism for diabetic kidney disease. The D2D3 form of uPAR acts as an immunotoxin and may cause diabetes and kidney disease | Science Translational Medicine
@salimhayek
@KeZhu3304
@ASNKidney https://t.co/cabppEkY6v
Meet the Author: Dr. Andrew Zloza (@AndrewZloza), an Associate Professor from @RushDOIM, @RushUniversity, @RushMedical, & senior author of “Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer,” out in #JITC! 1/6
It’s a wrap ! 11 years @RushMedical !
I have fond memories and hopefully have created lasting impact @RushDOIM.
It has been a privilege to lead our outstanding Department of Medicine.
Thank you !
Huge congratulations @JochenReiser on establishing and leaving a legacy of a thriving Dept of Medicine @ Rush and beginning an even more ambitious new journey @ utmb. 👏👏👏
Congrats @salimhayek@JochenReiser and team on a fabulous new study further linking extrarenal innate immune activation with glomerular injury and pathology. Very cool mechanism! 👏👏👏
Cracking down on cancers ! Great work by @AndrewZlozaand colleagues.
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory c… https://t.co/RjdyTRs7XM
Here is a deeper look at recent #JITC publication: “Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer” 1/5
Much thanks to the organizers of the @harvardmed@BrighamWomens “Skin Inflammation in Human Health and Disease 2023 International Conference” & especially to Rachael Clark for the invite! It was a great in-person experience, awesome audience, & well worth the COVID-delayed wait.
Much thanks to @NorthwesternMed@NUFeinbergMed Department of Microbiology-Immunology and Andrew Cogswell for hosting me last week! Great audience during my seminar with superb questions and wonderful faculty meetings!
The latest edition of the #JITC Reading List is out. Social Media Editor Dr. Praveen K. Bommareddy (@Praveen_IO) selects articles that add value to what readers find in the Journal for ImmunoTherapy of Cancer. Enjoy articles from the #immunotherapy field https://t.co/YP2u2blIRp
@DelgoffeLab@BReinfeld@jitcancer @JimAllisonPhD @PamSharmaMDPhD @PatrickHwuMD Thanks @DelgoffeLab - I almost missed this! – & yes, Coley had the right idea – now we are trying to implement “bugs as drugs” as cancer IT (https://t.co/961AUiuJuV) – with the flu season approaching, maybe tumors could benefit from an i.t. flu shot!? (https://t.co/JhvllK0xaf)
I am thrilled to announce that the Schenkel Lab will open it’s doors on Sept 15th @MDAndersonNews@MDA_UTHGrad. This is the culmination of many years of blood, sweat, and tears. I am over the moon excited to join such an incredible group of people focused on #endcancer. 1/
I am forever indebted to those who have taken me under their wing. @AndrewZloza for introducing me to Immunology, and sending me down an entirely different life path. Without your guidance, who knows where I would have ended up. Maybe back in New Jersey. 3/
Having previously shown that an intratumoural injection of a commercially available seasonal influenza vaccination can turn cold tumors into hot tumors, @KajalGupta04 has now looked into the potential antitumor effects of the inactivated SARS-CoV-2 virus: https://t.co/yenI8jMRfO